A spectroscopy approach to the study of virus infection in the endophytic fungus Epichloë festucae

<p>Abstract</p> <p>Background</p> <p>In this work we propose a rapid method based on visible and near-infrared (Vis-NIR) spectroscopy to determine the occurrence of double-stranded RNA (dsRNA) viruses in <it>Epichloë festucae </it>strains isolated from <it>Festuca rubra </it>plants. In addition, we examined the incidence of infections by <it>E. festucae </it>in populations of <it>F. rubra </it>collected in natural grasslands of Western Spain.</p> <p>Methods</p> <p>Vis-NIR spectra (400-2498 nm) from 124 virus-infected and virus-free <it>E. festucae </it>isolates were recorded directly from ground and freeze-dried mycelium. To estimate how well the spectra for uninfected and infected fungal samples could be differentiated, we used partial least-squares discriminant analysis (PLS1-DA) and several data pre-treatments to develop calibration models.</p> <p>Results</p> <p>Applying the best regression model, obtained with two sampling years and using standard normal variate (SNV) combined with first derivative transformation to a new validating data set (42 samples), we obtained a correct classification for 75% of the uninfected isolates and up to 86% of the infected isolates.</p> <p>Conclusions</p> <p>The results obtained suggest that Vis-NIR spectroscopy is a promising technology for detection of viral infections in fungal samples when an alternative faster approach is desirable. It provides a tool adequately exact and more time- and cost-saving than the conventional reference analysis.</p

International Impact of COVID-19 on the Diagnosis of Heart Disease

BACKGROUND The coronavirus disease 2019 (COVID-19) pandemic has adversely affected diagnosis and treatment of noncommunicable diseases. Its effects on delivery of diagnostic care for cardiovascular disease, which remains the leading cause of death worldwide, have not been quantified.OBJECTIVES The study sought to assess COVID-19`s impact on global cardiovascular diagnostic procedural volumes and safety practices.METHODS The International Atomic Energy Agency conducted a worldwide survey assessing alterations in cardiovascular procedure volumes and safety practices resulting from COVID-19. Noninvasive and invasive cardiac testing volumes were obtained from participating sites for March and April 2020 and compared with those from March 2019. Availability of personal protective equipment and pandemic-related testing practice changes were ascertained.RESULTS Surveys were submitted from 909 inpatient and outpatient centers performing cardiac diagnostic procedures, in 108 countries. Procedure volumes decreased 42% from March 2019 to March 2020, and 64% from March 2019 to April 2020. Transthoradc echocardiography decreased by 59%, transesophageat echocardiography 76%, and stress tests 78%, which varied between stress modalities. Coronary angiography (invasive or computed tomography) decreased 55% (p &lt; 0.001 for each procedure). hi multivariable regression, significantly greater reduction in procedures occurred for centers in countries with lower gross domestic product. Location in a low-income and lower-middle-income country was associated with an additional 22% reduction in cardiac procedures and less availability of personal protective equipment and teteheatth.CONCLUSIONS COVID-19 was associated with a significant and abrupt reduction in cardiovascular diagnostic testing across the globe, especially affecting the world's economically challenged. Further study of cardiovascular outcomes and COVID-19-related changes in care delivery is warranted. (C) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Evaluation of antioxidant and antibacterial activities of silver nanoparticles derived from Limonia acidissima L. fruit extract

In the rapidly expanding field of nanoscience and research, AgNPs and their diverse by-products have been acknowledged as having a green approach. Fruit extract of Limonia acidissima L. is capable of bio-reducing AgNO3 and stabilizing AgNPs. AgNPs distinctive absorption peak at 417 nm at pH 8 was visible on the UV-Vis spectrophotometer. The fruit extract contained bioactive chemicals, which may be the cause of the AgNPs bio-capping and stabilizing properties, according to Fourier transform infrared (FT-IR) spectroscopy. Using an X-ray diffractometer (XRD) examination, the AgNPs solid crystalline nature and size of 29.05 nm were investigated. Lastly, AFM and HR-TEM studies verified the AgNPs surface morphology, particularly their size and form. The DPPH assay method was used to measure the AgNPs capacity for radical scavenging. As compared to normal ascorbic acid and fruit extract (control), the AgNPs produced from the fruit extract demonstrated good antioxidant effectiveness. To evaluate the antibacterial activity of the AgNPs sample, it was additionally evaluated against E. coli, S. typhi, V. cholera, and S. aureus. With the greatest zone of inhibition and thus the strongest antibacterial activity, S. aureus (12.03 ± 0.043 mm) was the organism that displayed it. On the other hand, the least active strain was V. cholera (9.09 ± 0.013 mm). The data indicates that bio-fabricated silver nanoparticles (AgNPs) exhibited dose-dependent inhibitory efficacy together with a notable zone of inhibition. Additionally, S. aureus was shown to be more effective than V. cholera. Future health and pharmaceutical fields may benefit from the biocompatible method of separating AgNPs from L. acidissima fruit extract